ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

Company Overview

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a clinical-stage biopharmaceutical company dedicated to developing non-opioid therapies for acute pain and allergic conditions. The company’s proprietary drug discovery platform integrates high-throughput peptide screening with a novel vascular targeting technology designed to deliver therapeutic candidates directly to sensory nerve endings. By modulating receptor-mediated pathways involved in pain and itch transmission, ARS aims to provide fast-acting relief with a reduced risk of systemic side effects.

The company’s lead product candidate, CNV301, is in clinical development for emergency and procedural acute pain and is formulated for rapid onset and targeted action. ARS’s allergic disease program includes FRAGM-137, an intranasal peptide designed to alleviate seasonal and perennial allergic rhinitis, and FRAGM-189, which is being explored for skin and ocular manifestations of allergy. These candidates leverage the same platform technologies to address distinct therapeutic areas, underscoring ARS’s commitment to innovation across both pain management and allergy relief.

Founded in 2003 and headquartered in Van Nuys, California, ARS Pharmaceuticals combines in-house development expertise with strategic collaborations to advance its pipeline. The company has entered partnerships and licensing agreements to facilitate global development and commercialization of select candidates. ARS is led by President and Chief Executive Officer David Bourne, who brings extensive biopharma experience in clinical development and corporate strategy. The company’s multidisciplinary team of scientists and clinicians works to translate novel receptor-targeting approaches into safe and effective treatments.

Key Stats

• Today's Range: $16.15 to $16.81
• 50-Day Range: $12.10 to $18.20
• 52-Week Range: $8.91 to $18.90
• Volume: 881,491 shs
• Average Volume: 1.34 million shs
• Market Capitalization: $1.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Buy

ARS Pharmaceuticals Stock Analysis - MarketRank™

ARS Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 343rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ARS Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ARS Pharmaceuticals is -103.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ARS Pharmaceuticals is -103.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ARS Pharmaceuticals has a P/B Ratio of 6.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

30.27% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently decreased by 3.27%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ARS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

ARS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

30.27% of the float of ARS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in ARS Pharmaceuticals has recently decreased by 3.27%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.73

News Sentiment

ARS Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for ARS Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 3 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

MarketBeat Follows

3 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,639,888.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SPRY Stock Analysis - Frequently Asked Questions

How have SPRY shares performed this year?

ARS Pharmaceuticals' stock was trading at $10.55 at the start of the year. Since then, SPRY shares have increased by 56.3% and is now trading at $16.4850.

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). The firm earned $7.97 million during the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 6.94% and a negative net margin of 16.11%.
Read the conference call transcript.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ARS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SPRY
• CIK: 1671858
• Web: ars-pharma.com
• Phone: 206-456-2900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.00
• High Stock Price Target: $40.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +88.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $8 million
• Net Margins: -16.11%
• Pretax Margin: -15.82%
• Return on Equity: -6.94%
• Return on Assets: -5.60%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 11.00
• Quick Ratio: 10.74

Sales & Book Value

• Annual Sales: $89.15 million
• Price / Sales: 18.16
• Cash Flow: $0.01 per share
• Price / Cash Flow: 1,950.80
• Book Value: $2.64 per share
• Price / Book: 6.24

Miscellaneous

• Outstanding Shares: 98,210,000
• Free Float: 65,312,000
• Market Cap: $1.62 billion
• Optionable: Optionable
• Beta: 0.90